Wisp’s menopause consultation page names several oral options in the same treatment list. For someone asking about a progesterone capsule, the names matter: micronized progesterone and Provera should not be treated as one product simply because they appear under the same heading. The pharmacy label must identify what the clinician actually prescribes.

Reviewed September 29, 2026, this assessment separates that product question from Wisp’s consultation charge and the local-pharmacy purchase. It considers published service and transaction information only. No clinical assessment, medicine order, renewal or refund was tested, and the exact capsule remains unconfirmed.

In this article

A named option is not yet a selected preparation

Wisp’s menopause consultation page lists micronized progesterone, Provera and other oral options within its treatment menu. The menopause shop also describes hormone care, alongside other products. These records establish a relevant prescribing service, but they do not identify which option an individual would receive.

The words in the final prescription should be more specific than the website’s category heading. Ask for the active ingredient, physical form and intended route. Stella’s review considers another broad clinical menu whose capsule details must be confirmed separately. Comparing service access should not erase meaningful differences between the medicines that might be discussed at either service.

Provera and progesterone have different identities

The manufacturer’s Provera information identifies medroxyprogesterone acetate tablets, a progestin. By contrast, the Prometrium label identifies micronized progesterone capsules. Their appearance near one another in a care menu does not make their active ingredients, formulation or product-specific evidence identical.

The progesterone-purpose guide helps frame the next question: why is the particular medicine being proposed within the complete hormone plan? Neither this distinction nor a brand preference establishes which option is appropriate for a reader. A prescriber must explain the actual recommendation, and the pharmacy information should match it. This review supplies no substitution, conversion or switching advice.

The capsule ingredients belong to the eventual dispensing label

Wisp’s consultation description does not provide a full excipient list or manufacturer for the micronized progesterone option. It therefore cannot establish whether a selected order contains peanut oil, gelatin or another substance relevant to an ingredient concern. A medicine-category listing is too broad to answer that question.

For comparison only, the Prometrium labeling record lists peanut oil and gelatin and identifies peanut allergy as a restriction. It does not prove Wisp’s pharmacy would dispense Prometrium. The capsule-excipient guide encourages a label-specific inquiry with the pharmacist. The response should identify the actual preparation rather than reassure someone based solely on the hormone’s name.

The advertised care fee leaves a separate pharmacy transaction

The consultation offer starts at $33 per month for consultation, follow-ups and monthly care-team access. It expressly says prescribed medication is paid for at the local pharmacy. The offer therefore does not establish a $33 price for progesterone capsules or an all-inclusive hormone plan.

Ask what the selected care payment covers, its billing commitment and the pharmacy’s charge for the actual prescription. The page describes same-day transmission if prescribed; that is not confirmation of dispensing, stock or clinical approval. The available FAQ does not establish complete eligibility terms, so broad state-availability wording cannot settle every individual access condition. A submitted request is not proof that the medicine will be supplied.

Recurring care still depends on a valid prescription

Wisp’s terms describe subscriptions with recurring payments, but prescription renewals require a completed intake and clinical review. An expired prescription prevents the automatic prescription renewal described there. These conditions are relevant to continuity without creating a guarantee of uninterrupted supply or approval.

The terms require cancellation at least forty-eight hours before the next refill or renewal period to avoid its charge. The follow-up guide distinguishes commercial renewal from clinical reassessment. Confirm which subscription rules apply to the chosen consultation and medicine arrangement. A cancellation decision about a service should never be confused with instructions about whether or how to continue an existing prescription.

Refund language should be read before assuming flexibility

The platform terms generally make product sales final and do not allow returns. They reserve discretion for refunds or replacements in specified problems, including unavailable or damaged products, and describe local-pharmacy payment separately. This review did not establish a guaranteed refund for dissatisfaction with a clinical recommendation or an unwanted medicine effect.

Those commercial limits do not reduce the importance of reporting a health concern. MedlinePlus discusses possible dizziness and drowsiness with oral progesterone. The drowsiness guide can help organize practical questions for a professional. A patient needs a clinical answer about the medicine regardless of whether a transaction qualifies for a refund.

The consultation should leave fewer ambiguities than the storefront

The Wisp offer supports a clinical conversation about several hormone options. A useful outcome of that conversation would be a specific medicine identity, explanation of purpose and clear division between clinician follow-up and pharmacy information. The public pages cannot establish those individualized answers in advance.

Joi’s review contrasts a service listing progesterone capsules and cream with separate quarterly fees. Wisp’s oral-options list raises a different identity question, involving differently named active drugs. Neither menu establishes equivalence or a preferred treatment. Assess the documented service and obtain the missing prescription details, without using a care price or marketing category as a proxy for capsule safety or benefit.

Sources for this article

Source type matters. A provider page describes an offer; an exact product label describes that medicine.

  1. Wisp: menopause consultationDated provider offer naming micronized progesterone and other oral options; starting care charge excludes local-pharmacy medicine, eligibility FAQ extraction incomplete · Checked 2026-09-28
  2. Wisp: menopause care shopProvider menopause-care and product directory; care menu is not a completed prescription · Checked 2026-09-29
  3. Pfizer Medical: Provera medroxyprogesterone acetateManufacturer medicine information; active-drug/tablet identity to distinguish Provera from micronized progesterone capsules, no dosing or study-result transfer · Checked 2026-09-29
  4. DailyMed: Prometrium progesterone capsulesExact Acertis product labeling updated July23,2026; oral micronized progesterone, peanut oil/gelatin and peanut-allergy restriction, not a label for every provider or generic · Checked 2026-09-29
  5. Wisp: terms of useDated platform transaction terms; prescription renewal review,48-hour cancellation and discretionary product remedies; not individual legal advice · Checked 2026-09-28
  6. MedlinePlus: ProgesteroneFederal medication information; oral-capsule identity, possible dizziness/drowsiness and professional discussion only; public schedules not reproduced as reader instructions · Checked 2026-09-29
How we use evidence ↗